Special Issue

Molecular Biomarkers for Risk and Prognosis of Cancer

Message from the Guest Editor

There are critical needs to identify and validate novel biomarkers for risk and prognosis of different cancers aiming to reduce public health burden of human malignancies. Biomarkers can be at different layers, for example, genetic variants, genes, CpG sites, proteins, metabolites, glycans, micro-RNAs, etc., using body fluids such as blood or other tissues. With the development of high-throughput technologies, it is now possible to screen the human genome, transcriptome, proteome, metabolome, glycome, etc. in an agnostic way to identify novel biomarker candidates for cancers. There are also emerging new strategies integrating genomics and other types of -omics data in uncovering novel biomarker candidates. It is also an attractive area of using newly identified biomarkers for risk and prognosis prediction of human malignancies. In this Special Issue, we will publish original research and review articles that provide new insights into the role of different layers of biomarkers for risk and prognosis of different malignancies.

Guest Editor

Dr. Lang Wu

Cancer Epidemiology Division, Population Sciences in the Pacific Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, HI 96813, USA

Deadline for manuscript submissions

closed (30 September 2021)

Cancers

mdpi.com/journal/
cancers

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)